| Year |
Citation |
Score |
| 2019 |
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. PMID 31227432 DOI: 10.1016/J.Clgc.2019.02.010 |
0.31 |
|
| 2019 |
Kraus RD, Barsky A, Ji L, Garcia Santos PM, Cheng N, Groshen S, Vapiwala N, Ballas LK. The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study. Advances in Radiation Oncology. 4: 96-102. PMID 30706016 DOI: 10.1016/J.Ijrobp.2018.07.332 |
0.381 |
|
| 2018 |
Ballas LK, Luo C, Chung E, Kishan A, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. Phase I trial of SBRT to the prostate fossa following prostatectomy. International Journal of Radiation Oncology, Biology, Physics. PMID 30605751 DOI: 10.1016/J.Ijrobp.2018.12.047 |
0.303 |
|
| 2018 |
Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. Bmc Cancer. 18: 970. PMID 30309325 DOI: 10.1186/S12885-018-4880-X |
0.324 |
|
| 2018 |
Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn DI, Chung E, Abreu A, Hamilton AS. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clinical Genitourinary Cancer. PMID 29483045 DOI: 10.1016/J.Clgc.2018.01.018 |
0.357 |
|
| 2017 |
Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB. Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clinical Genitourinary Cancer. PMID 28958673 DOI: 10.1016/J.Clgc.2017.08.016 |
0.34 |
|
| 2017 |
Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, et al. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 8: 52193-52210. PMID 28881723 DOI: 10.18632/Oncotarget.13386 |
0.308 |
|
| 2017 |
Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 28668277 DOI: 10.1016/J.Clgc.2017.06.002 |
0.342 |
|
| 2017 |
Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss B, ... ... Groshen S, et al. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28559462 DOI: 10.1158/1078-0432.Ccr-16-2647 |
0.327 |
|
| 2017 |
Mohrbacher A, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman E, Maurer BJ. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: a California Cancer Consortium Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420721 DOI: 10.1158/1078-0432.Ccr-17-0234 |
0.316 |
|
| 2017 |
Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, et al. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer (Oxford, England : 1990). 77: 13-20. PMID 28347919 DOI: 10.1016/J.Ejca.2017.02.020 |
0.329 |
|
| 2017 |
Lee SC, Grant E, Sheth P, Garcia AA, Desai B, Ji L, Groshen S, Hwang D, Yamashita M, Hovanessian-Larsen L. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. PMID 28150325 DOI: 10.7863/Ultra.16.05060 |
0.306 |
|
| 2017 |
Kraus R, Ji L, Jennelle R, Groshen S, Ballas LK. Active surveillance: Do low-income patients adhere to the protocol? Journal of Clinical Oncology. 35: 53-53. DOI: 10.1200/Jco.2017.35.6_Suppl.53 |
0.35 |
|
| 2017 |
Tuscano J, Groshen S, Tsao-Wei D, Maverakis E, Kaesberg PR, Siddiqi T, Popplewell L, Ailawadhi S, Htut M, Chen RW, Kirschbaum M, Schroeder MT, Jonas BA, Wun T, Palmisiano N, et al. a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis Blood. 130: 4086-4086. DOI: 10.1182/Blood.V130.Suppl_1.4086.4086 |
0.354 |
|
| 2017 |
Sadeghi S, Groshen S, Parikh R, Mortazavi A, Dorff T, Hoimes C, Doyle L, Quinn D, Newman E, Lara P. Phase II California cancer consortium trial of gemcitabine-eribulin combination (ge) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): Efficacy report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038) Annals of Oncology. 28: v302. DOI: 10.1093/Annonc/Mdx371.014 |
0.349 |
|
| 2017 |
Sadeghi S, Groshen S, Parikh R, Mortazavi A, Dorff T, Hoimes C, Pal S, Levine E, Doyle L, Quinn D, Newman E, Lara P. Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038) European Journal of Cancer. 72: S197. DOI: 10.1016/S0959-8049(17)30706-2 |
0.353 |
|
| 2016 |
Bian SX, Routman D, Liu J, Yang D, Groshen S, Zada G, Trakul N, Wong MK, Yu C, Chang EL. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. Journal of Neurosurgery. 125: 31-39. PMID 27903181 DOI: 10.3171/2016.8.Gks161359 |
0.355 |
|
| 2016 |
Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. Bmc Cancer. 16: 360. PMID 27282289 DOI: 10.1186/S12885-016-2370-6 |
0.331 |
|
| 2016 |
Piatek CI, Tagawa ST, Wei-Tsai D, Hanna D, Weitz IC, O'Connell C, Rochanda L, Groshen S, Liebman HA. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin. Thrombosis Research. 140: S174. PMID 27161687 DOI: 10.1016/S0049-3848(16)30131-1 |
0.387 |
|
| 2016 |
Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, et al. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood & Cancer. PMID 27092812 DOI: 10.1002/Pbc.25994 |
0.335 |
|
| 2016 |
DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, et al. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884555 DOI: 10.1200/Jco.2015.65.4889 |
0.322 |
|
| 2016 |
Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, et al. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. The Oncologist. PMID 26786262 DOI: 10.1634/Theoncologist.2015-0319 |
0.395 |
|
| 2016 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, et al. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. The Prostate. PMID 26771938 DOI: 10.1002/Pros.23151 |
0.352 |
|
| 2016 |
Bulbul A, Rashad S, Tsao-Wei D, Groshen S, Huber M, Weitz IC. Pattern of Care and Association of Response with Rituxan Among Primary and Secondary Immune Thrombocytopenia Patients Blood. 128: 4920-4920. DOI: 10.1182/Blood.V128.22.4920.4920 |
0.338 |
|
| 2016 |
Kelly KR, Wu K, Tsao-Wei D, Groshen S, Triche TJ, Mohrbacher A, Chang G, Fernando D, Siddiqi IN, Coffey M, Gill G, Lee A, Carew JS, Nawrocki ST. Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood. 128: 4507-4507. DOI: 10.1182/Blood.V128.22.4507.4507 |
0.372 |
|
| 2016 |
El-Khoueiry A, Gitlitz B, Cole S, Tsao-Wei D, Goldkorn A, Quinn D, Lenz H, Nieva J, Dorff T, Oswald M, Berg J, Menendez X, Karakozian K, Krasnoperov V, Liu R, ... ... Groshen S, et al. A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) European Journal of Cancer. 69: S11. DOI: 10.1016/S0959-8049(16)32623-5 |
0.301 |
|
| 2015 |
Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5057-63. PMID 26567365 DOI: 10.1158/1078-0432.Ccr-15-0035 |
0.311 |
|
| 2015 |
Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R, Alexopoulos S. Kidney Transplantation in the Hispanic Population. Clinical Transplantation. PMID 26529140 DOI: 10.1111/Ctr.12662 |
0.303 |
|
| 2015 |
Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. Journal of Surgical Oncology. 112: 125-32. PMID 26171686 DOI: 10.1002/Jso.23973 |
0.327 |
|
| 2015 |
Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood & Cancer. 62: 1739-46. PMID 26153194 DOI: 10.1002/Pbc.25594 |
0.329 |
|
| 2015 |
Stany MP, Stone PJ, Felix JC, Amezcua CA, Groshen S, Ye W, Kyser KL, Howard RS, Zahn CM, Muderspach LI, Lentz SE, Chernofsky MR. Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 34: 379-84. PMID 26061072 DOI: 10.1097/Pgp.0000000000000188 |
0.338 |
|
| 2015 |
Mata DA, Groshen S, Von Rundstedt FC, Skinner DG, Stadler WM, Cote RJ, Stein JP, Lerner SP. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. Journal of Surgical Oncology. 111: 923-8. PMID 25873574 DOI: 10.1002/Jso.23903 |
0.35 |
|
| 2015 |
Skinner EC, Fairey AS, Groshen S, Daneshmand S, Cai J, Miranda G, Skinner DG. Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer. The Journal of Urology. PMID 25823791 DOI: 10.1016/J.Juro.2015.03.101 |
0.356 |
|
| 2015 |
Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. Plos One. 10: e0117758. PMID 25693195 DOI: 10.1371/Journal.Pone.0117758 |
0.351 |
|
| 2015 |
von Rundstedt FC, Mata DA, Groshen S, Stein JP, Skinner DG, Stadler WM, Cote RJ, Kryvenko ON, Godoy G, Lerner SP. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. Bju International. 116: 44-9. PMID 25413313 DOI: 10.1111/Bju.12997 |
0.394 |
|
| 2015 |
Galligan BM, Tsao-Wei D, Groshen S, Kirschabum M, O'Donnell R, Kaesberg PR, Siddiqui T, Popplewell L, Sikander A, Myo H, Chen R, DiPersio JF, Palmisiano ND, Claxton DF, Newman EM, et al. Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma Blood. 126: 3977-3977. DOI: 10.1182/Blood.V126.23.3977.3977 |
0.341 |
|
| 2015 |
Pinski J, Schally AV, Groshen S, Denice TW, Liu SV, Quinn D, Dorff T, Athreya K, Yu S, Xiong S. 2539 A phase II trial of AEZS-108 in castration and taxane resistant prostate cancer European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31358-2 |
0.302 |
|
| 2015 |
Hu B, Fairey A, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins R, Den R, et al. MP37-19 AXIN2 EXPRESSION PREDICTS PROSTATE CANCER RECURRENCE AND MEDIATES AN INVASIVE, TUMORIGENIC PHENOTYPE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1282 |
0.362 |
|
| 2015 |
Routman DM, Bian SX, Ji L, Groshen S, Apuzzo MLJ, Yu C, Chang EL. Survival Outcomes for Patients With 5+ Versus Single or 2 to 4 Brain Metastases Undergoing Stereotactic Radiosurgery (SRS) International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.821 |
0.302 |
|
| 2015 |
Bian SX, Korah MP, Whitaker TR, Ji L, Groshen S, Chung E. No Acute Cardiac Effects Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.599 |
0.323 |
|
| 2014 |
Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urologic Oncology. 32: 1108-15. PMID 25443274 DOI: 10.1016/J.Urolonc.2013.10.021 |
0.318 |
|
| 2014 |
Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6277-83. PMID 25278449 DOI: 10.1158/1078-0432.Ccr-14-0489 |
0.341 |
|
| 2014 |
Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 17: 359-65. PMID 25245366 DOI: 10.1038/Pcan.2014.37 |
0.318 |
|
| 2014 |
Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. Bmc Research Notes. 7: 256. PMID 24755475 DOI: 10.1186/1756-0500-7-256 |
0.305 |
|
| 2014 |
Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Research. 74: 2857-68. PMID 24648349 DOI: 10.1158/0008-5472.Can-13-2003 |
0.311 |
|
| 2014 |
Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 83: 262-4. PMID 24332121 DOI: 10.1016/J.Urology.2013.10.030 |
0.328 |
|
| 2014 |
Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. The Journal of Urology. 191: 40-7. PMID 23911605 DOI: 10.1016/J.Juro.2013.07.061 |
0.393 |
|
| 2014 |
Mohrbacher A, Syed I, Merin N, Ramsingh G, Groshen S, Chaudhary P. Microtransplantation: HLA-Mismatched Allogeneic Cellular Therapy of Acute Myeloid Leukemia (HMMACT) Blood. 124: 5944-5944. DOI: 10.1182/Blood.V124.21.5944.5944 |
0.35 |
|
| 2014 |
Hu B, Fairey A, Madhav A, Xu T, Yang D, Li M, Groshen S, Stephens C, Quinn D, Kim P, Virk N, Wang L, Martin SE, Gill I, Goldkorn A. MP41-09 AXIN2 PREDICTS PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1226 |
0.308 |
|
| 2013 |
Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 11: 416-22. PMID 24099865 DOI: 10.1016/J.Clgc.2013.07.011 |
0.342 |
|
| 2013 |
Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clinical Trials (London, England). 10: 720-34. PMID 23983156 DOI: 10.1177/1740774513497539 |
0.301 |
|
| 2013 |
Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatric Blood & Cancer. 60: 1801-8. PMID 23813912 DOI: 10.1002/Pbc.24643 |
0.305 |
|
| 2013 |
Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, Cote RJ. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer. 119: 756-65. PMID 23319010 DOI: 10.1002/cncr.27763 |
0.32 |
|
| 2013 |
Ailawadhi S, Liebman HA, Groshen S, Tsao-Wei DD, Rochanda L, Aldoss I, O'Connell C, Wang T, Duran C, Rickles F. Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma Blood. 122: 5350-5350. DOI: 10.1182/Blood.V122.21.5350.5350 |
0.348 |
|
| 2013 |
Fairey A, Skinner D, Groshen S, Faber K, Cai J, Miranda G, Skinner E. 1415 Effect Of Studer Pouch Versus T-Pouch Orthotopic Ileal Bladder Substitution On Late Complications And Surgical Re-Intervention In Bladder Cancer Patients Undergoing Radical Cystectomy: Secondary Analyses From The Usc-Star Randomized Trial The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2769 |
0.317 |
|
| 2012 |
Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1155-63. PMID 22700000 DOI: 10.2967/Jnumed.111.098624 |
0.34 |
|
| 2012 |
DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2679-86. PMID 22421195 DOI: 10.1158/1078-0432.Ccr-11-3201 |
0.347 |
|
| 2012 |
Ting MC, Liao CP, Yan C, Jia L, Groshen S, Frenkel B, Roy-Burman P, Coetzee GA, Maxson R. An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Disease Models & Mechanisms. 5: 366-74. PMID 22279083 DOI: 10.1242/Dmm.008458 |
0.318 |
|
| 2012 |
Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 574-8. PMID 22198425 DOI: 10.1097/Jto.0B013E31823F43Ca |
0.405 |
|
| 2012 |
Pinski J, Dorff TB, Hawes D, Tsao-Wei D, Quinn DI, Goldkorn A, Liskovsky G, Vogelzang N, Groshen S, Ji L. Updated Analysis of a Combination Herbal Supplement Trial in Biochemically Recurrent Prostate Cancer Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33523-7 |
0.325 |
|
| 2012 |
Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckman A, Daneshmand S, Groshen S, Raghavan D, Korn C, Massopust K, Ketchens C, Aparicio AM, Dorff TB. Gemcitabine, Oxaliplatin, and Paclitaxel (GOT) on a 2-Weekly Schedule in Patients (PTS) with Refractory Germ Cell Carcinoma: A Phase II Study Conducted at the University of Southern California Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33425-6 |
0.317 |
|
| 2012 |
Skinner E, Fairey A, Groshen S, Cai J, Eisenberg M, Miranda G, Skinner D. 1156 Randomized Trial Of Studer Pouch Versus T-Pouch Orthotopic Urinary Diversion In Bladder Cancer Patients Interim Analysis Of Effect On Renal Function At 3 Years The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1380 |
0.317 |
|
| 2011 |
Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. Journal of Gastrointestinal Oncology. 2: 77-84. PMID 22811834 DOI: 10.3978/J.Issn.2078-6891.2010.025 |
0.389 |
|
| 2011 |
Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, et al. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. Plos One. 6: e28141. PMID 22163280 DOI: 10.1371/Journal.Pone.0028141 |
0.327 |
|
| 2011 |
Kaur P, Ward B, Saha B, Young L, Groshen S, Techy G, Lu Y, Atkinson R, Taylor CR, Ingram M, Imam SA. Human breast cancer histoid: an in vitro 3-dimensional co-culture model that mimics breast cancer tissue. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 59: 1087-100. PMID 22034518 DOI: 10.1369/0022155411423680 |
0.308 |
|
| 2011 |
Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3443-9. PMID 21810677 DOI: 10.1200/Jco.2010.34.4028 |
0.414 |
|
| 2011 |
Sposto R, Groshen S. A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. Contemporary Clinical Trials. 32: 694-703. PMID 21554993 DOI: 10.1016/J.Cct.2011.04.009 |
0.325 |
|
| 2011 |
Dong D, Stapleton C, Luo B, Xiong S, Ye W, Zhang Y, Jhaveri N, Zhu G, Ye R, Liu Z, Bruhn KW, Craft N, Groshen S, Hofman FM, Lee AS. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Research. 71: 2848-57. PMID 21467168 DOI: 10.1158/0008-5472.Can-10-3151 |
0.301 |
|
| 2011 |
Birkhahn M, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. Bju International. 108: 660-4. PMID 21223479 DOI: 10.1111/J.1464-410X.2010.09978.X |
0.419 |
|
| 2011 |
Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatric Blood & Cancer. 56: 191-201. PMID 20830775 DOI: 10.1002/Pbc.22767 |
0.301 |
|
| 2011 |
Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. International Journal of Cancer. Journal International Du Cancer. 128: 726-31. PMID 20473863 DOI: 10.1002/Ijc.25370 |
0.4 |
|
| 2011 |
Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. American Journal of Clinical Oncology. 34: 27-31. PMID 20142723 DOI: 10.1097/Coc.0B013E3181Cae766 |
0.369 |
|
| 2011 |
Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Young LL, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, et al. Abstract 2258: Using molecular alterations to predict bladder cancer prognosis independent of clinicopathologic parameters and cigarette smoke exposure Cancer Research. 71: 2258-2258. DOI: 10.1158/1538-7445.Am2011-2258 |
0.306 |
|
| 2011 |
Mitra A, Tsao-Wei D, Dorff T, Groshen S, Miranda G, Schuckman A, Daneshmand S, Gill I, Skinner D, Skinner E, Quinn D. 1589 Influence Of Smoking History On Bladder Cancer Patient Outcome Following Radical Cystectomy The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1639 |
0.312 |
|
| 2011 |
Mitra A, Castelao J, Hawes D, Tsao-Wei D, Jiang X, Shi S, Young L, Datar R, Skinner E, Stein J, Groshen S, Yu M, Ross R, Skinner D, Cortessis V, et al. 1057 PROTEIN ALTERATIONS PREDICT BLADDER CANCER OUTCOME INDEPENDENT OF CLINICOPATHOLOGIC PROGNOSTIC CRITERIA AND TOBACCO SMOKE EXPOSURE Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1094 |
0.3 |
|
| 2010 |
Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5011-8. PMID 20876796 DOI: 10.1158/1078-0432.Ccr-10-1105 |
0.335 |
|
| 2010 |
Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. The Prostate. 70: 1359-70. PMID 20623636 DOI: 10.1002/Pros.21173 |
0.324 |
|
| 2010 |
Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. The Prostate. 70: 1692-700. PMID 20564320 DOI: 10.1002/Pros.21204 |
0.348 |
|
| 2010 |
Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1764-9. PMID 20215557 DOI: 10.1158/1078-0432.Ccr-09-3287 |
0.305 |
|
| 2010 |
Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemotherapy and Pharmacology. 65: 979-88. PMID 20062993 DOI: 10.1007/S00280-009-1236-X |
0.372 |
|
| 2010 |
Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. European Urology. 57: 12-20. PMID 19762144 DOI: 10.1016/J.Eururo.2009.09.013 |
0.405 |
|
| 2010 |
Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 78-86. PMID 19622587 DOI: 10.1093/Annonc/Mdp280 |
0.303 |
|
| 2010 |
Jiang X, Castelao JE, Yuan J, Groshen S, Stern MC, Conti DV, Cortessis VK, Coetzee GA, Pike MC, Gago-Dominguez M. Abstract 860: Hypertension, diuretics, and antihypertensives in relation to bladder cancer Cancer Research. 70: 860-860. DOI: 10.1158/1538-7445.Am10-860 |
0.304 |
|
| 2010 |
Lerner SP, Stadler W, Groshen S, Cai J, Mitra AP, Tuazon E, Skinner D, Raghavan D, Esrig D, Steinberg G, Klotz L, Hall C, Cote RP. 1715 Cell Cycle Regulatory Protein Alterations In A Prospective Study Of Patients With Organ-Confined Bladder Cancer Following Radical Cystectomy The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1562 |
0.349 |
|
| 2009 |
LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. Bmc Medical Genomics. 2: 67. PMID 19948057 DOI: 10.1186/1755-8794-2-67 |
0.335 |
|
| 2009 |
Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3929-37. PMID 19620494 DOI: 10.1200/Jco.2008.18.5744 |
0.368 |
|
| 2009 |
Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens. Analytical Biochemistry. 392: 117-25. PMID 19505431 DOI: 10.1016/J.Ab.2009.06.001 |
0.301 |
|
| 2009 |
Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 4: 176-84. PMID 19421002 DOI: 10.4161/Epi.4.3.8694 |
0.302 |
|
| 2009 |
Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clinical Genitourinary Cancer. 7: 43-50. PMID 19213668 DOI: 10.3816/Cgc.2009.N.008 |
0.416 |
|
| 2009 |
Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1020-5. PMID 19171714 DOI: 10.1200/Jco.2007.15.7628 |
0.34 |
|
| 2009 |
Ailawadhi S, Keng M, Mohrbacher A, Thara E, Yang D, Sher T, Patel MP, Miller KC, Groshen S, Chanan-Khan AA. Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma. Blood. 114: 4895-4895. DOI: 10.1182/Blood.V114.22.4895.4895 |
0.362 |
|
| 2009 |
Keng M, Chanan-Khan AA, Thara E, Yang D, Mohrbacher A, Groshen S, Ailawadhi S. Ethnic Disparities in Multiple Myeloma: A Comparative Analysis of Hispanic Patients. Blood. 114: 4875-4875. DOI: 10.1182/Blood.V114.22.4875.4875 |
0.358 |
|
| 2009 |
Streeter O, Benitez P, Vicini F, Mehta V, Quiet C, Kuske R, Hayes M, Arthur D, Kuerer H, Strom E, Freedman G, Keisch M, DiPetrillo T, Khan D, Hudes R, ... Groshen S, et al. 3-Year Follow-Up of the Partial Breast Irradiation Trial for DCIS Using the MammoSite® Brachytherapy Balloon Catheter. Cancer Research. 69: 952-952. DOI: 10.1158/0008-5472.Sabcs-09-952 |
0.381 |
|
| 2009 |
Shariat SF, Karakiewicz PI, Fradet Y, Ashfaq R, Bolenz C, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Groshen S, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, et al. IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS The Journal of Urology. 181: 628. DOI: 10.1016/S0022-5347(09)61764-X |
0.343 |
|
| 2008 |
Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, Jones LW, Imam SA. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. The Prostate. 68: 1681-8. PMID 18712716 DOI: 10.1002/Pros.20836 |
0.311 |
|
| 2008 |
Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow JH, Danenberg K, Danenberg P. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome Annals of Oncology. 19: 1853-1859. PMID 18641005 DOI: 10.1093/Annonc/Mdn402 |
0.388 |
|
| 2008 |
Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1734-41. PMID 18550579 DOI: 10.1093/Annonc/Mdn368 |
0.388 |
|
| 2008 |
Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM, Lee AS. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Research. 68: 498-505. PMID 18199545 DOI: 10.1158/0008-5472.Can-07-2950 |
0.333 |
|
| 2008 |
Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics and Genomics. 18: 161-8. PMID 18192902 DOI: 10.1097/Fpc.0B013E3282F4Aea6 |
0.375 |
|
| 2008 |
Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, Jones LW, Imam SA. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. The Prostate. 68: 78-84. PMID 18008331 DOI: 10.1002/Pros.20670 |
0.304 |
|
| 2008 |
Shariat SF, Karakiewicz PI, Fradet Y, Ashfaq R, Stein JP, Bastian PJ, Nielsen ME, Suardi N, Montorsi F, Groshen S, Muller SC, Rigaud J, Heukamp LC, Netto GJ, Lerner SP, et al. Combination Of Cell Cycle Regulating Bio-Markers Improves Prognosis In Patients With Organ Confined Urothelial Cancer At Radical Cystectomy The Journal of Urology. 72: 578-578. DOI: 10.1016/S0022-5347(08)61698-5 |
0.361 |
|
| 2007 |
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3712-8. PMID 17704420 DOI: 10.1200/Jco.2006.08.8021 |
0.357 |
|
| 2007 |
Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer (Amsterdam, Netherlands). 58: 220-30. PMID 17659810 DOI: 10.1016/J.Lungcan.2007.06.015 |
0.314 |
|
| 2007 |
Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Human Pathology. 38: 1547-52. PMID 17640713 DOI: 10.1016/J.Humpath.2007.03.014 |
0.37 |
|
| 2007 |
Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, Groshen S, Lieskovsky G, Skinner DG. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. The Journal of Urology. 177: 876-81; discussion 8. PMID 17296365 DOI: 10.1016/J.Juro.2006.10.043 |
0.312 |
|
| 2007 |
Kang TY, Nichols P, Skinner E, Groshen S, Valin G, Ye W, Raghavan D. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response. Bju International. 99: 1024-7. PMID 17244277 DOI: 10.1111/J.1464-410X.2006.06738.X |
0.366 |
|
| 2007 |
Yang D, Schultheis AM, Lurje G, Iqbal S, Chang H, Zhang W, Groshen S, Gordon M, Nagashima F, Lenz H. Tissue factor promoter polymorphism as a prognostic factor in patients with metastatic colon cancer Journal of Clinical Oncology. 25: 4108-4108. DOI: 10.1200/Jco.2007.25.18_Suppl.4108 |
0.318 |
|
| 2007 |
Mohrbacher A, Gutierrez M, Murgo AJ, Kummar S, Reynolds CP, Maurer BJ, Groshen S, Vergara L, Kang MH, Yang AS. Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies. Blood. 110: 2581-2581. DOI: 10.1182/Blood.V110.11.2581.2581 |
0.31 |
|
| 2006 |
Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clinical Colorectal Cancer. 6: 305-11. PMID 17241515 DOI: 10.3816/Ccc.2006.N.049 |
0.349 |
|
| 2006 |
Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG. Salvage Radical Prostatectomy: Quality of Life Outcomes and Long-Term Oncological Control of Radiorecurrent Prostate Cancer Journal of Urology. 176: 2025-2032. PMID 17070244 DOI: 10.1016/J.Juro.2006.07.075 |
0.38 |
|
| 2006 |
Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Research. 66: 7849-53. PMID 16912156 DOI: 10.1158/0008-5472.Can-06-1660 |
0.424 |
|
| 2006 |
Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenetics and Genomics. 16: 555-63. PMID 16847424 DOI: 10.1097/01.Fpc.0000220563.44724.6D |
0.386 |
|
| 2006 |
Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and Deep (pT2b) Muscle Invasion in Pathological Staging of Bladder Cancer Following Radical Cystectomy Journal of Urology. 176: 493-499. PMID 16813876 DOI: 10.1016/J.Juro.2006.03.065 |
0.349 |
|
| 2006 |
Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and Genomics. 16: 475-83. PMID 16788380 DOI: 10.1097/01.Fpc.0000220562.67595.A5 |
0.328 |
|
| 2006 |
Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. Detection of Occult Lymph Node Metastases in Locally Advanced Node-Negative Prostate Cancer Journal of Clinical Oncology. 24: 2735-2742. PMID 16782914 DOI: 10.1200/Jco.2005.05.4767 |
0.314 |
|
| 2006 |
Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer Urology. 67: 1247-1252. PMID 16697447 DOI: 10.1016/J.Urology.2005.12.009 |
0.367 |
|
| 2006 |
Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma Journal of Neuro-Oncology. 78: 271-276. PMID 16628476 DOI: 10.1007/S11060-005-9093-X |
0.395 |
|
| 2006 |
Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis Cancer. 106: 2021-2027. PMID 16583432 DOI: 10.1002/Cncr.21828 |
0.421 |
|
| 2006 |
Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study Journal of Clinical Oncology. 24: 500-506. PMID 16421427 DOI: 10.1200/Jco.2005.03.6400 |
0.372 |
|
| 2006 |
Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 7: 67-88. PMID 16354126 DOI: 10.2217/14622416.7.1.67 |
0.424 |
|
| 2006 |
Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma Cancer. 106: 172-179. PMID 16323194 DOI: 10.1002/Cncr.21582 |
0.397 |
|
| 2006 |
Raghavan D, Davis MS, Tsao-Wei D, Ross R, Groshen S. Increased late toxicity in 12–20 year survivors of germ cell tumors (GCT) Journal of Clinical Oncology. 24: 4509-4509. DOI: 10.1200/Jco.2006.24.18_Suppl.4509 |
0.384 |
|
| 2006 |
Park DJ, Zhang W, Gordon M, Yang DY, Ladner R, Iqbal S, Groshen S, Vallbohmer D, Lenz H, Fazzone W. Lack of association with epidermal growth factor receptor gene polymorphisms with clinical outcome in patients with advanced colorectal cancer treated with platinum-based chemotherapy Journal of Clinical Oncology. 24: 3079-3079. DOI: 10.1200/Jco.2006.24.18_Suppl.3079 |
0.314 |
|
| 2006 |
Yang D, Vallböhmer D, Zhang W, Iqbal S, El-Khoueiry A, Gordon M, Park D, Azuma M, Groshen S, Danenberg KD, Lenz H. Intratumoral mRNA levels predict clinical outcome in patients with metastatic colorectal cancer treated in a prospective clinical trial with 5-FU and oxaliplatin Journal of Clinical Oncology. 24: 10010-10010. DOI: 10.1200/Jco.2006.24.18_Suppl.10010 |
0.358 |
|
| 2005 |
Beil SJ, George B, Wu L, Cai J, Patten N, Young L, Groshen S, Datar RH, Cote RJ. Comparison of p53 genotype and phenotype: Site of mutation predicts outcome in patients with bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9561. PMID 27944023 DOI: 10.1200/Jco.2005.23.16_Suppl.9561 |
0.319 |
|
| 2005 |
Bono A, Goebell PJ, Groshen S, Lehmann J, Studer U, Torti FM, Abol-Enein H, Bassi P, Boyer M, Coppin CML, Cortesi E, Hall RR, Horwich A, Malmstrom PU, Martinez-Pineiro JA, et al. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. European Urology. 48: 189-201. PMID 15939530 DOI: 10.1016/J.Eururo.2005.04.005 |
0.387 |
|
| 2005 |
Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy Journal of Neuro-Oncology. 72: 185-189. PMID 15926000 DOI: 10.1007/S11060-004-2062-Y |
0.414 |
|
| 2005 |
Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: Clinical and pathological characteristics in 768 male patients Journal of Urology. 173: 1163-1168. PMID 15758728 DOI: 10.1097/01.Ju.0000149679.56884.0F |
0.375 |
|
| 2005 |
Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. Journal of the American College of Surgeons. 200: 336-44. PMID 15737843 DOI: 10.1016/J.Jamcollsurg.2004.10.035 |
0.351 |
|
| 2005 |
Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma Journal of Clinical Oncology. 23: 741-750. PMID 15613700 DOI: 10.1200/Jco.2005.01.128 |
0.33 |
|
| 2005 |
Weber JS, Snively J, Sian S, Delto J, Groshen S, Gee C, Scotland R. Randomized phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with Alum for resected stages IIC/III and IV melanoma Journal of Clinical Oncology. 23: 2506-2506. DOI: 10.1200/Jco.2005.23.16_Suppl.2506 |
0.58 |
|
| 2004 |
Agafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3600. PMID 28014348 DOI: 10.1200/Jco.2004.22.14_Suppl.3600 |
0.387 |
|
| 2004 |
Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy: Prognostic significance Neurology. 63: 2159-2161. PMID 15596770 DOI: 10.1212/01.Wnl.0000145599.06491.71 |
0.324 |
|
| 2004 |
Chang A, Cai J, Miranda G, Groshen S, Skinner D, Stein JP. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder Journal of Urology. 172: 2182-2186. PMID 15538227 DOI: 10.1097/01.Ju.0000143487.20280.Ed |
0.342 |
|
| 2004 |
Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Anticancer Research. 24: 2391-400. PMID 15330189 |
0.311 |
|
| 2004 |
Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Waldman F, Cote RJ. The International Bladder Cancer Bank: proposal for a new study concept. Urologic Oncology-Seminars and Original Investigations. 22: 277-284. PMID 15283883 DOI: 10.1016/S1078-1439(03)00175-3 |
0.34 |
|
| 2004 |
Daneshmand S, Stein JP, Lesser T, Quek ML, Nichols PW, Miranda G, Cai J, Groshen S, Skinner EC, Skinner DG. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. The Journal of Urology. 172: 81-4. PMID 15201742 DOI: 10.1097/01.Ju.0000132131.64727.Ff |
0.394 |
|
| 2004 |
Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. The Journal of Experimental Medicine. 199: 1213-21. PMID 15123743 DOI: 10.1084/Jem.20031462 |
0.316 |
|
| 2004 |
Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma Neurology. 62: 1210-1212. PMID 15079029 DOI: 10.1212/01.Wnl.0000118300.82017.F4 |
0.379 |
|
| 2004 |
Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1007-13. PMID 14981105 DOI: 10.1200/Jco.2004.05.174 |
0.601 |
|
| 2004 |
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer The Journal of Urology. 171: 640-645. PMID 14713777 DOI: 10.1097/01.Ju.0000108664.39035.51 |
0.381 |
|
| 2004 |
Aparicio A, Iqbal S, Yang D, Groshen S, Park D, Garcia A, Lenz HJ. Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL) Journal of Clinical Oncology. 22: 3773-3773. DOI: 10.1200/Jco.2004.22.90140.3773 |
0.4 |
|
| 2004 |
Park DJ, Yun J, Yang DY, Iqbal S, Press O, Groshen S, Gordon M, Zhang W, Lenz H-. Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy Journal of Clinical Oncology. 22: 3627-3627. DOI: 10.1200/Jco.2004.22.90140.3627 |
0.368 |
|
| 2004 |
Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber JS. Immune gene polymorphisms predict overall survival for stage IV melanoma patients treated with biochemotherapy Journal of Clinical Oncology. 22: 7550-7550. DOI: 10.1200/Jco.2004.22.14_Suppl.7550 |
0.315 |
|
| 2004 |
Stadler WM, Cote R, Learner S, Stein J, Groshen S. Phase III Trial Assessing 3 Cycles of MVAC in Organ-Confined Bladder Cancer with p53 Oncology Times. 26: 4. DOI: 10.1097/01.Cot.0000291486.35033.7B |
0.311 |
|
| 2004 |
Lentz SE, Muderspach LI, Felix JC, Ye W, Groshen S, Amezcua CA. Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients Obstetrics and Gynecology. 103: 1204-1210. DOI: 10.1097/01.Aog.0000125869.78251.5E |
0.321 |
|
| 2004 |
Zhang W, Gordon M, Yun J, Press O, Yang D, Groshen S, Lenz H. Association between dinucleotide repeat(CA) polymorphism of nuclear factor kappa-bata(NF-KB) and local recurrence of stage II/III rectal cancer patients treated with chemoradiation International Journal of Radiation Oncology Biology Physics. 60. DOI: 10.1016/J.Ijrobp.2004.07.312 |
0.328 |
|
| 2003 |
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 98: 955-961. PMID 12942562 DOI: 10.1002/Cncr.11569 |
0.398 |
|
| 2003 |
Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1301-12. PMID 12684398 |
0.546 |
|
| 2003 |
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 864-70. PMID 12610186 DOI: 10.1200/Jco.2003.06.132 |
0.599 |
|
| 2003 |
Stapfer M, Hu J, Wei D, Groshen S, Beart RW. Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery Journal of Surgical Oncology. 82: 121-130. PMID 12561068 DOI: 10.1002/Jso.10168 |
0.301 |
|
| 2003 |
Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 97: 186-200. PMID 12491520 DOI: 10.1002/Cncr.11045 |
0.55 |
|
| 2003 |
Zhang W, Lu B, Gil J, Yang D, Groshen S, Lenz H. Interleukin-8 (IL-8) promoter region gene polymorphism predicts pelvic recurrence after chemo-radiation in patients with rectal cancer International Journal of Radiation Oncology Biology Physics. 57. DOI: 10.1016/S0360-3016(03)01303-8 |
0.315 |
|
| 2002 |
Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer Journal of the National Cancer Institute. 94: 936-942. PMID 12072547 DOI: 10.1093/Jnci/94.12.936 |
0.379 |
|
| 2002 |
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer International Journal of Colorectal Disease. 17: 46-49. PMID 12018454 DOI: 10.1007/S003840100358 |
0.302 |
|
| 2002 |
Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology, Biology, Physics. 52: 397-405. PMID 11872285 DOI: 10.1016/S0360-3016(01)02655-4 |
0.381 |
|
| 2002 |
Grossfeld GD, Carroll PR, Lindeman N, Meng M, Groshen S, Feng AC, Hawes D, Cote RJ. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology. 59: 97-102. PMID 11796289 DOI: 10.1016/S0090-4295(01)01476-5 |
0.405 |
|
| 2001 |
Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. The Pharmacogenomics Journal. 1: 65-70. PMID 11913730 DOI: 10.1038/Sj.Tpj.6500012 |
0.327 |
|
| 2001 |
Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy Journal of Clinical Oncology. 19: 4298-4304. PMID 11731512 DOI: 10.1200/Jco.2001.19.23.4298 |
0.402 |
|
| 2001 |
Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3836-47. PMID 11559721 DOI: 10.1200/Jco.2001.19.18.3836 |
0.575 |
|
| 2001 |
Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. HER-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease Journal of Urology. 166: 1514-1519. PMID 11547123 DOI: 10.1016/S0022-5347(05)65822-3 |
0.369 |
|
| 2001 |
Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM, Salonga D, Groshen S, Tsao-Wei DD, DeMeester TR, Hölscher AH, Danenberg PV. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. The Journal of Surgical Research. 99: 301-6. PMID 11469901 DOI: 10.1006/Jsre.2001.6186 |
0.315 |
|
| 2001 |
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients Journal of Clinical Oncology. 19: 666-675. PMID 11157016 DOI: 10.1200/Jco.2001.19.3.666 |
0.411 |
|
| 2001 |
Safra T, Groshen S, Jeffers RNS, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer. 91: 90-100. PMID 11148564 DOI: 10.1002/1097-0142(20010101)91:1<90::Aid-Cncr12>3.0.Co;2-A |
0.402 |
|
| 2000 |
Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. Journal of the National Cancer Institute. 92: 1805-11. PMID 11078757 DOI: 10.1093/Jnci/92.22.1805 |
0.31 |
|
| 2000 |
Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 Annals of Oncology. 11: 1029-1033. PMID 11038041 DOI: 10.1023/A:1008365716693 |
0.327 |
|
| 2000 |
Formenti SC, Lieskovsky G, Skinner D, Tsao-Wei DD, Groshen S, Petrovich Z. Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve- sparing prostatectomy Urology. 56: 453-458. PMID 10962314 DOI: 10.1016/S0090-4295(00)00677-4 |
0.365 |
|
| 2000 |
Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW, Hall FL. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Research. 60: 3343-7. PMID 10910035 |
0.513 |
|
| 2000 |
Liu D, Naritoku WY, Tsao-Wei D, Groshen S, Neville MA, Taylor CR, Cote RJ, Imam SA. LEA.135 expression: an independent and favorable prognostic biomarker for patients with primary invasive breast cancer. International Journal of Cancer. Journal International Du Cancer. 89: 224-9. PMID 10861497 DOI: 10.1002/1097-0215(20000520)89:3<224::Aid-Ijc3>3.0.Co;2-B |
0.413 |
|
| 2000 |
Formenti SC, Groshen S, Florentine B, Park MJ, Danenberg PV. Low HER 2/NEU gene expression is associated with pathological response to primary paclitaxel and radiation in locally advanced breast cancer (LABC) International Journal of Radiation Oncology Biology Physics. 48: 143. DOI: 10.1016/S0360-3016(00)80080-2 |
0.316 |
|
| 2000 |
Lord RV, Maranzana A, Gee C, Groshen S, Oberg S, Gastal OL, Crookes PF, Bremner CG, Peters JH, Hashemi M, Mason R, DeMeester TR. Risk factors for gastroesophageal reflux disease Gastroenterology. 118: A1267. DOI: 10.1016/S0016-5085(00)80915-4 |
0.525 |
|
| 1999 |
Datar RH, Naritoku WY, Li P, Tsao-Wei D, Groshen S, Taylor CR, Imam SA. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Gynecologic Oncology. 74: 338-45. PMID 10479490 DOI: 10.1006/Gyno.1999.5506 |
0.305 |
|
| 1999 |
Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ. The influence of margin width on local control of ductal carcinoma in situ of the breast New England Journal of Medicine. 340: 1455-1461. PMID 10320383 DOI: 10.1056/Nejm199905133401902 |
0.334 |
|
| 1999 |
Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunology, Immunotherapy : Cii. 48: 9-21. PMID 10235484 DOI: 10.1007/S002620050543 |
0.591 |
|
| 1999 |
Chatterjee SJ, Youssefzadeh D, Stein JP, Shi S, Groshen S, Skinner DG, Cote RJ. THE COMBINED EFFECTS OF p53, p21, and Rb EXPRESSION IN BLADDER CANCER PROGRESSION The Journal of Urology. 314. DOI: 10.1097/00005392-199904020-00259 |
0.317 |
|
| 1999 |
Spicer DV, Groshen S, Doroshow JH, Synold T, Gandara D, Russell C, Muggia F. Phase II randomized study of paclitaxel and paclitaxel + PSC 833 for advanced breast cancer European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81689-X |
0.302 |
|
| 1998 |
Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones PA, Skinner DG, Cote RJ. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. Journal of the National Cancer Institute. 90: 1072-9. PMID 9672255 DOI: 10.1093/Jnci/90.14.1072 |
0.34 |
|
| 1998 |
Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. Association of p27(Kip1) levels with recurrence and survival in patients with stage C prostate carcinoma Journal of the National Cancer Institute. 90: 916-920. PMID 9637141 DOI: 10.1093/Jnci/90.12.916 |
0.375 |
|
| 1998 |
Stein JP, Esrig D, Freeman JA, Grossfeld GD, Ginsberg DA, Cote RJ, Groshen S, Boyd SD, Lieskovsky G, Skinner DG. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology. 51: 951-5. PMID 9609632 DOI: 10.1016/S0090-4295(98)00099-5 |
0.347 |
|
| 1998 |
Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy Journal of Clinical Oncology. 16: 309-316. PMID 9440758 DOI: 10.1200/Jco.1998.16.1.309 |
0.333 |
|
| 1998 |
Corte RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi S-, Tran Q-, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF. Elevated and Absent pRb Expression is Associated With Bladder Cancer Progression and has Cooperative Effects With p53 The Journal of Urology. 160: 1936-1937. DOI: 10.1016/S0022-5347(01)62456-X |
0.37 |
|
| 1997 |
Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, Watkins K, Muggia F, Florentine B, Press M, Danenberg K, et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 39: 1059-68. PMID 9392545 DOI: 10.1016/S0360-3016(97)00506-3 |
0.398 |
|
| 1997 |
Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 3223-9. PMID 9336359 DOI: 10.1200/Jco.1997.15.10.3223 |
0.338 |
|
| 1997 |
Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, Safra T, Morrow CP. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin) Gynecologic Oncology. 66: 290-294. PMID 9264578 DOI: 10.1006/Gyno.1997.4778 |
0.391 |
|
| 1997 |
Simons AJ, Ker R, Groshen S, Gee C, Anthone GJ, Ortega AE, Vukasin P, Ross RK, Beart RW. Variations in treatment of rectal cancer: the influence of hospital type and caseload. Diseases of the Colon and Rectum. 40: 641-6. PMID 9194456 DOI: 10.1007/Bf02140891 |
0.592 |
|
| 1997 |
Quan WD, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, Mitchell MS. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m Journal of Clinical Oncology. 15: 2103-2110. PMID 9164224 DOI: 10.1200/Jco.1997.15.5.2103 |
0.334 |
|
| 1997 |
Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, Baranda J, Casagrande Y, Groshen S, Silberman H. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report Cancer. 79: 1767-1775. PMID 9128994 DOI: 10.1002/(Sici)1097-0142(19970501)79:9<1767::Aid-Cncr19>3.0.Co;2-W |
0.368 |
|
| 1997 |
Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. Journal of the National Cancer Institute. 89: 219-27. PMID 9017002 DOI: 10.1093/Jnci/89.3.219 |
0.372 |
|
| 1997 |
Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature. 385: 123-5. PMID 8990112 DOI: 10.1038/385123B0 |
0.313 |
|
| 1996 |
Freeman JA, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC, Groshen S, Lieskovsky G, Skinner DG. Urethral recurrence in patients with orthotopic ileal neobladders. The Journal of Urology. 156: 1615-9. PMID 8863551 DOI: 10.1016/S0022-5347(01)65462-4 |
0.366 |
|
| 1996 |
Douer PID, Levine CA, Anderson WF, Gordon M, Groshen S, Khan A, Mohrbacher A, Muggia F, Shibata D. High-Dose Chemotherapy and Autologous Bone Marrow Plus Peripheral Blood Stem Cell Transplantation for Patients with Lymphoma or Metastatic Breast Cancer: Use of Marker Genes to Investigate Hematopoietic Reconstitution in Adults. University of Southern California, Norris Cancer Center, Los Angeles, California Human Gene Therapy. 7: 669-684. PMID 8845392 DOI: 10.1089/Hum.1996.7.5-669 |
0.335 |
|
| 1996 |
Moyses HM, Morrow CP, Muderspach LI, Roman LD, Vasilev SA, Petrovich Z, Groshen SL, Klement V. Residual disease in the uterus after preoperative radiotherapy and hysterectomy in stage IB cervical carcinoma. American Journal of Clinical Oncology. 19: 433-8. PMID 8823468 DOI: 10.1097/00000421-199610000-00001 |
0.352 |
|
| 1996 |
Formenti SC, Lieskovsky G, Simoneau AR, Skinner D, Groshen S, Chen SC, Petrovich Z. Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy Journal of Urology. 155: 616-619. PMID 8558674 DOI: 10.1016/S0022-5347(01)66467-X |
0.34 |
|
| 1996 |
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival Journal of Clinical Oncology. 14: 176-182. PMID 8558194 DOI: 10.1200/Jco.1996.14.1.176 |
0.396 |
|
| 1996 |
Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen SC, Groshen S, Simoneau A, Skinner EC, Lieskovsky G, Boyd SD, Cote RJ, Skinner DG. Transitional Cell Carcinoma Involving the Prostate with a Proposed Staging Classification for Stromal Invasion The Journal of Urology. 156: 1071-1076. DOI: 10.1016/S0022-5347(01)65705-7 |
0.317 |
|
| 1995 |
Petrovich Z, Lieskovsky G, Freeman J, Luxton G, Groshen S, Formenti S, Baert L, Chen SC, Skinner DG. Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate Cancer. 76: 1621-1628. PMID 8635067 DOI: 10.1002/1097-0142(19951101)76:9<1621::Aid-Cncr2820760919>3.0.Co;2-O |
0.384 |
|
| 1995 |
Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 76: 833-9. PMID 8625187 DOI: 10.1002/1097-0142(19950901)76:5<833::Aid-Cncr2820760518>3.0.Co;2-M |
0.421 |
|
| 1995 |
Formenti SC, Meyerowitz BE, Ell K, Muderspach L, Groshen S, Leedham B, Klement V, Morrow PC. Inadequate adherence to radiotherapy in Latina immigrants with carcinoma of the cervix: Potential impact on disease free survival Cancer. 75: 1135-1140. PMID 7850712 DOI: 10.1002/1097-0142(19950301)75:5<1135::Aid-Cncr2820750513>3.0.Co;2-M |
0.344 |
|
| 1995 |
Stein JP, Cote RJ, Freeman JA, Esrig D, Elmajian DA, Groshen S, Skinner EC, Boyd SD, Lieskovsky G, Skinner DG. Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. The Journal of Urology. 154: 1329-33. PMID 7658531 DOI: 10.1016/S0022-5347(01)66850-2 |
0.321 |
|
| 1995 |
Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. European Journal of Cancer (Oxford, England : 1990). 31: 1306-10. PMID 7577041 DOI: 10.1016/0959-8049(95)00326-E |
0.39 |
|
| 1995 |
Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, Sherrod AE, Groshen S, Taylor CR. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Annals of Surgery. 222: 415-23; discussion 4. PMID 7574923 DOI: 10.1097/00000658-199522240-00001 |
0.379 |
|
| 1995 |
Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis Journal of the National Cancer Institute. 87: 1603-1612. PMID 7563203 DOI: 10.1093/Jnci/87.21.1603 |
0.377 |
|
| 1994 |
Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 402-11. PMID 8113848 DOI: 10.1200/Jco.1994.12.2.402 |
0.324 |
|
| 1994 |
Yamada AH, Lieskovsky G, Petrovich Z, Chen SC, Groshen S, Skinner DG. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer American Journal of Clinical Oncology: Cancer Clinical Trials. 17: 277-285. PMID 8048388 DOI: 10.1097/00000421-199408000-00001 |
0.391 |
|
| 1994 |
Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53 and tumor progression in bladder cancer. The New England Journal of Medicine. 331: 1259-64. PMID 7935683 DOI: 10.1056/Nejm199411103311903 |
0.322 |
|
| 1994 |
Uziely B, Groshen S, Jeffers S, Morris M, Russell C, Roman L, Muderspach L, Muggia F. Paditaxel (Taxol) in heavily pretreated ovarian cancer: Antitumor activity and complications Annals of Oncology. 5: 827-833. PMID 7848885 DOI: 10.1093/Oxfordjournals.Annonc.A059012 |
0.414 |
|
| 1994 |
Freeman JA, Lieskovsky G, Grossfeld G, Esrig D, Stein JP, Cook DW, Petrovich Z, Chen SC, Groshen S, Skinner DG. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate. Urology. 44: 719-25. PMID 7526528 DOI: 10.1016/S0090-4295(94)80214-9 |
0.367 |
|
| 1993 |
Freeman JA, Lieskovsky G, Cook DW, Petrovich Z, Chen S, Groshen S, Skinner DG. Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: intermediate findings. The Journal of Urology. 149: 1029-34. PMID 8483203 DOI: 10.1016/S0022-5347(17)36288-2 |
0.364 |
|
| 1993 |
Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J, Curtin J, Morrow CP. Intraperitoneal Carboplatin and Etoposide for Persistent Epithelial Ovarian Cancer: Analysis of Results by Prior Sensitivity to Platinum-Based Regimens Gynecologic Oncology. 50: 232-238. PMID 8375739 DOI: 10.1006/Gyno.1993.1198 |
0.397 |
|
| 1993 |
Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang XQ, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action Annals of the New York Academy of Sciences. 690: 153-166. PMID 8368734 DOI: 10.1111/J.1749-6632.1993.Tb44005.X |
0.33 |
|
| 1993 |
Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up Journal of Clinical Oncology. 11: 2090-2100. PMID 8229123 DOI: 10.1200/Jco.1993.11.11.2090 |
0.358 |
|
| 1992 |
Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma Journal of Clinical Oncology. 10: 1158-1164. PMID 1607920 DOI: 10.1200/Jco.1992.10.7.1158 |
0.303 |
|
| 1991 |
Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. The Journal of Urology. 145: 459-64; discussion 4. PMID 1997689 DOI: 10.1016/S0022-5347(17)38368-4 |
0.384 |
|
| 1991 |
Lira-Puerto V, Silva A, Morris M, Martinez R, Groshen S, Morales-Canfield F, Tenorio F, Muggia F. Phase II trial of carboplatin or iproplatin in cervical cancer Cancer Chemotherapy and Pharmacology. 28: 391-396. PMID 1914084 DOI: 10.1007/Bf00685695 |
0.389 |
|
| 1991 |
Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: A 20-year follow-up study Journal of Clinical Oncology. 9: 1650-1661. PMID 1875222 DOI: 10.1200/Jco.1991.9.9.1650 |
0.353 |
|
| 1991 |
Kempf RA, Irwin LE, Menendez L, Chandrasoma P, Groshen S, Melbye W, Moore T, Pentecost M, Quinn M, Sapozink M, Schwinn CP, Sherrod A, Stewart M, Wolf W, Muggia FM. Limb salvage surgery for bone and soft tissue sarcoma: A Phase II pathologic study of preoperative intraarterial cisplatin Cancer. 68: 738-743. PMID 1855173 DOI: 10.1002/1097-0142(19910815)68:4<738::Aid-Cncr2820680413>3.0.Co;2-J |
0.358 |
|
| 1991 |
Rarick MU, Montgomery T, Groshen S, Sullivan-Halley J, Jamin D, Mazumder A, Gill PS, Loureiro C, Levine AM. Intravenous immunoglobulin in the treatment of human immunodeficiency virus-related thrombocytopenia American Journal of Hematology. 38: 261-266. PMID 1746533 DOI: 10.1002/Ajh.2830380402 |
0.302 |
|
| 1990 |
Rosen PP, Groshen S. Factors influencing survival and prognosis and early breast carcinoma (T1N0M0-T1N1M0): Assessment of 644 patients with median follow-up of 18 years Surgical Clinics of North America. 70: 937-962. PMID 2371651 DOI: 10.1016/S0039-6109(16)45190-X |
0.371 |
|
| 1989 |
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma Journal of Clinical Oncology. 7: 355-366. PMID 2918331 DOI: 10.1200/Jco.1989.7.3.355 |
0.378 |
|
| 1989 |
Rosen PP, Groshen S, Kinne DW, Hellman S. Nonmammary malignant neoplasms in patients with stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. A long-term follow-up study American Journal of Clinical Oncology: Cancer Clinical Trials. 12: 369-374. PMID 2801596 DOI: 10.1097/00000421-198910000-00001 |
0.351 |
|
| 1989 |
Keller SM, Groshen S, Kaiser LR. Blood transfusion and lung cancer recurrence The Annals of Thoracic Surgery. 48: 746. PMID 2554830 DOI: 10.1016/0003-4975(89)90823-0 |
0.372 |
|
| 1989 |
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years Journal of Clinical Oncology. 7: 1239-1251. PMID 2549203 DOI: 10.1200/Jco.1989.7.9.1239 |
0.37 |
|
| 1989 |
Lewis LJ, Lavey RS, Groshen S, Prosnitz LR. Postoperative radiatiun therapy for upper aerodigestive tract cancers with positive surgical margins prognostic factors International Journal of Radiation Oncology Biology Physics. 17: 230. DOI: 10.1016/0360-3016(89)90846-8 |
0.311 |
|
| 1986 |
O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy Journal of Clinical Oncology. 4: 1604-1614. PMID 3021920 DOI: 10.1200/Jco.1986.4.11.1604 |
0.399 |
|
| 1984 |
Daly JM, Hearne B, Dunaj J, LePorte B, Vikram B, Strong E, Green M, Mugglo F, Groshen S, DeCosse JJ. Nutritional rehabilitation in patients with advanced head and neck cancer receiving radiation therapy The American Journal of Surgery. 148: 514-520. PMID 6385745 DOI: 10.1016/0002-9610(84)90379-9 |
0.37 |
|
| 1984 |
Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Brochstein J, Shank B, Reid A, Groshen S, O'Reilly RJ. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood. 63: 649-56. PMID 6365204 DOI: 10.1182/Blood.V63.3.649.649 |
0.315 |
|
| 1983 |
Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Shank B, Reid A, Groshen S, O'Reilly RJ. Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood. 62: 381-8. PMID 6347274 DOI: 10.1182/Blood.V62.2.381.381 |
0.322 |
|
| Show low-probability matches. |